Lack of association of the cyclooxygenase 8473 T>C polymorphism with lung cancer: Evidence from 9841 subjects

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 8, 2011, Pages 1941-1945

  Pan, Feng ^a   Tian, Jing ^a   Pan, Yueyin ^a   Zhang, Ying ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; Lung cancer; Meta analysis; Polymorphism

Indexed keywords

EID: 84863239501     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Bi N, Yang M, Zhang L, et al (2010). Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res, 16, 2383-90.
2. Campa D, Hung RJ, Mates D, et al (2005). Lack of association between polymorphisms in inflammatory genes and lung cancer risk. Cancer Epidemiol Biomarkers Prev, 14, 538-9.
3. Campa D, Zienolddiny S, Maggini V, et al (2004). Association of a common polymorphism in the cyclooxygenase 2 gene with risk of non-small cell lung cancer. Carcinogenesis, 25, 229-35.
4. Cochran WG (1954). The combination of estimates from different experiments. Biometrics, 10, 101-29.
5. Cok SJ, Morrison AR (2001). The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem, 276, 23179-85.
6. DerSimonian R, Laird N (1986). Meta-analysis in clinical trials. Control Clin Trials, 7, 177-88.
7. Egger M, Davey Smith G, Schneider M, et al(1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315, 629-34.
8. Faul F, Erdfelder E, Buchner A, et al(2009). Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods, 41, 1149-60.
9. Han S, Roman J (2006). COX-2 inhibitors suppress lung cancer cell growth by inducing p21 via COX-2 independent signals. Lung Cancer, 51, 283-96.
10. Harris RE, Beebe-Donk J, Alshafie GA (2007). Reduced risk of human lung cancer by selective cyclooxygenase 2 (COX-2) blockade: results of a case control study. Int J Biol Sci, 3, 328-34.
11. Hecht SS (1999). Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst, 91, 1194-210.
12. Hedelin M, Chang ET, Wiklund F, et al (2007). Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. Int J Cancer, 120, 398-405.
13. Hida T, Kozaki K, Ito H, et al (2002). Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res, 8, 2443-7.
14. Higgins JP, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Stat Med, 21, 1539-58.
15. Hu Z, Miao X, Ma H, et al (2005). A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. Lung Cancer, 48, 11-7.
16. Jemal A, Center MM, DeSantis C, et al(2010). Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev, 19, 1893-907.
17. Jemal A, Siegel R, Xu J, et al(2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
18. Khuri FR, Wu H, Lee JJ, et al (2001). Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res, 7, 861-7.
19. Lim WY, Chen Y, Ali SM, et al (2011). Polymorphisms in inflammatory pathway genes, host factors and lung cancer risk in Chinese female never-smokers. Carcinogenesis, 32, 522-9.
20. Liu CJ, Hsia TC, Wang RF, et al (2010). Interaction of cyclooxygenase 2 genotype and smoking habit in Taiwanese lung cancer patients. Anticancer Res, 30, 1195-9.
21. Liu F, He Y, Peng X, et al (2010). Association of the 8473T>C cyclooxygenase-2 (COX-2) gene polymorphism with lung cancer risk in Asians. Asian Pac J Cancer Prev, 11, 1257-62.
22. Mantel N, Haenszel W (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst, 22, 719-48.
23. Martey CA, Pollock SJ, Turner CK, et al (2004). Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am J Physiol Lung Cell Mol Physiol, 287, L981-91.
24. Park JM, Choi JE, Chae MH, et al (2006). Relationship between cyclooxygenase 8473T>C polymorphism and the risk of lung cancer: a case-control study. BMC Cancer, 6, 70.
25. Petkova DK, Clelland C, Ronan J, et al (2004). Overexpression of cyclooxygenase-2 in non-small cell lung cancer. Respir Med, 98, 164-72.
26. Peto R, Darby S, Deo H, et al (2000). Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ, 321, 323-9.
27. Qadri SS, Wang JH, Coffey JC, et al (2005). Surgically induced accelerated local and distant tumor growth is significantly attenuated by selective COX-2 inhibition. Ann Thorac Surg, 79, 990-5.
28. Reyes-Gibby CC, Spitz MR, Yennurajalingam S, et al (2009). Role of inflammation gene polymorphisms on pain severity in lung cancer patients. Cancer Epidemiol Biomarkers Prev, 18, 2636-42.
29. Rioux N, Castonguay A (1998). Prevention of NNK-induced lung tumorigenesis in A/J mice by acetylsalicylic acid and NS-398. Cancer Res, 58, 5354-60.
30. Shishodia S, Potdar P, Gairola CG, et al(2003). Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesi, 24, 1269-79.
31. Sørensen M, Autrup H, Tjønneland A, et al(2005). A genetic polymorphism in prostaglandin synthase 2 (8473, T->C) and the risk of lung cancer. Cancer Lett, 226, 49-54.
32. Stroup DF, Berlin JA, Morton SC, et al (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA, 283, 2008-12.
33. Ulivi P, Mercatali L, Zoli W, et al (2008). Serum free DNA and COX-2 mRNA expression in peripheral blood for lung cancer detection. Thorax, 63, 843-4.
34. Vogel U, Christensen J, Wallin H, et al (2008). Polymorphisms in genes involved in the inflammatory response and interaction with NSAID use or smoking in relation to lung cancer risk in a prospective study. Mutat Res, 639, 89-100.
35. Wardlaw SA, March TH, Belinsky SA (2000). Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions. Carcinogenesis, 21, 1371-7.
36. Wolff H, Saukkonen K, Anttila S, et al (1998). Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res, 58, 4997-5001.
37. Wu YC, Su LJ, Wang HW, et al (2010). Co-overexpression of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 adversely affects the postoperative survival in non-small cell lung cancer. J Thorac Oncol, 5, 1167-74.
38. Yao R, Rioux N, Castonguay A, et al(2000). Inhibition of COX-2 and induction of apoptosis: two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis. Exp Lung Res, 26, 731-42.
39. Zintzaras E (2010). Impact of Hardy-Weinberg equilibrium deviation on allele-based risk effect of genetic association studies and meta-analysis. Eur J Epidemiol, 25, 553-60.
40. Zou YF, Wang F, Feng XL, et al (2011). Association of NFKB1-94ins/delATTG promoter polymorphism with susceptibility to autoimmune and inflammatory diseases: a meta-analysis. Tissue Antigens, 77, 9-17.